Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Nab-paclitaxel and Cisplatin for Esophageal Squamous Cell Carcinoma
NCT03964753Phase 2Recruiting
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Apr 2019
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of paclitaxel in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by The Fourth Hospital of Hebei Medical University. Primary endpoint: Overall Survival at 5 years. Started Apr 2019; status: recruiting.
02
Drugs
paclitaxel
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT03964753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03964753.